USPTO 2015–2025 USPTO PatentsView US Corporation

ELI Lilly AND Company

USPTO PatentsView assignee record - 523 granted patents across 38 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

523

Total patents granted

CPC technology areas

13.3

Avg claims per patent

+62%

5-year filing velocity

The verdict

ELI holds 523 US patents across 38 technology areas, rank #865 of 50,000 tracked assignees.

#865
of 50,000 US assignees by volume: Top 4%
by Innovation Score (59.7/100): 13.3
avg claims per patent: +62%
filing velocity, last 5 yrs

Portfolio overview

ELI Lilly AND Company has been granted 523 US utility patents between 2015 and 2025, placing ELI Lilly AND Company at rank #865 across all assignees tracked by PlainPatent. This portfolio spans 38 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.3 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, ELI Lilly AND Company is one of the more focused assignees in the PatentsView dataset. By volume, ELI sits between Lyft, Inc. (526 patents, rank #861) and University Of Virginia Patent Foundation (520 patents, rank #869) - the closest US assignees by grant volume. The composite Innovation Score of 59.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 323 grants, compared with 200 in the 2015–2019 window, a +62% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. ELI Lilly AND Company's 13.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 38 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark ELI Lilly AND Company against peers pursuing similar technology classes.

Lyft

526
Xiaomi

526
Echostar L L C

525
Transportation IP…

524
United States of…

523
ELI Lilly AND ◀

523
China Academy OF…

520
Fresenius Medical…

520
University of Vir…

520

What this shows ELI holds 523 patents at rank #865, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near ELI

By rank, the assignees closest to #865 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in ELI's primary technology class.

ELI's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

60 Top 4% higher than 96% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

ELI Lilly AND Company patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	43	8.2%
2016	42	8.0%
2017	35	6.7%
2018	41	7.8%
2019	39	7.5%
2020	45	8.6%
2021	53	10.1%
2022	56	10.7%
2023	52	9.9%
2024	62	11.9%
2025	55	10.5%

Which technologies does ELI Lilly AND Company patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 320

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 234

C07D - HETEROCYCLIC COMPOUNDS 176

C07K - PEPTIDES 139

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 99

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 29

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 19

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 14

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 12

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 10

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 10

A61J - CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE 6

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 5

A01K - ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS 5

B65D - CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES 5

Top 15 of 38 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Standard

Velocity Accelerating

Where it ranks

Overall rank by patents

#865

Across all tracked assignees

Innovation Score

59.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does ELI Lilly AND Company hold?

ELI Lilly AND Company holds 523 US granted patents filed between 2015 and 2025, spanning 38 technology areas.

What is ELI Lilly AND Company's Innovation Score?

ELI Lilly AND Company has an Innovation Score of 59.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does ELI Lilly AND Company focus on?

ELI Lilly AND Company's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 320 patents. The company has filed patents in 38 CPC subclasses total.

Is ELI Lilly AND Company's patent filing rate increasing or decreasing?

ELI Lilly AND Company's recent filing velocity is +62% compared to the prior five-year period. This indicates accelerating innovation.

What does claim depth mean for ELI Lilly AND Company's patents?

ELI Lilly AND Company's patents average 13.3 claims each. This falls within the standard range, providing solid legal coverage.

How is the ELI Lilly AND Company patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

ELI's 523 grants land it in the top 4% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - ELI ranks #865 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.